MAOA Informations sur la molécule
Molecule Name
Monoamine oxidase A
Alias de la molécule
MAOA
Drug Development Progress
Nombre de médicaments cliniques1
Nombre de médicaments commercialisés2
Phase de R&D la plus avancéeApproved
Alias de la cible
EC 1.4.3，EC:1.4.3.4，Monoamine oxidase type A，Amine Oxidase [Flavin-Containing] A，MAO-A，MAOA，Monoamine Oxidase A，EC 1.4.3.4，BRNRS
Contexte de la molécule
MAOA, Monoamine oxidase-A is an FAD-dependent mitochondrial enzyme, which, together with its isoenzyme MAO-B, catalyses the oxidative deamination of structurally diverse amines. MAOA is mainly involved in the metabolism of monoamine neurotransmitters, such as such as serotonin, dopamine, and norepinephrine. Inhibitors of MAOA are in clinical use for affective disorders and is approved to treat despression.
MAOA Liste de produits
You Have Viewed 0 Of 0 Results
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| CB-2202 | CB-2202 | Phase 2 Clinical | Cennerv Pharma | Depressive Disorder, Major | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Toloxatone | MD-69276 | Approved | Umoril, Humoryl, Perenum | France | Depression | null | 1984-01-01 | Depression | Details | |
| Metaxalone (Primus Pharmaceuticals) | Approved | Primus Pharmaceuticals Inc | United States | Muscle Spasticity | Primus Pharmaceuticals Inc | 2015-06-01 | Muscle Spasticity | Details |